Facebook Twitter LinkedIn Google Plus RSS

Insmed hopes to net $94M from stock offering

By ,

Insmed Incorporated, a Bridgewater-based biopharmaceutical company, announced Tuesday that it has priced an offering of 8.9 million shares of common stock at $11.25 per share.

Insmed said in a news release that it expected to receive net proceeds of approximately $94 million from the offering, based on approximately $100 million in gross proceeds minus underwriting discounts and commissions, and other expenses. The proceeds will be used to fund further development of Insmed’s Arikayce product to treat lung disease patients.

The offering is expected to close on about Aug. 18, Insmed said. Leerink Partners LLC is the bookrunner, with Piper Jaffray & Co. and JMP Securities LLC acting as lead managers, and H.C. Wainwright & Co. LLC, as co-manager.


As officials react to announcement that Revel will close, A.C. mayor is critical of decision

The 10 unfriendliest cities in the country: New Jersey puts two on the list — including No. 1

EDA votes to approve more than $27M in Grow NJ incentives

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy